🇺🇸 Everolimus Tab. in United States
36 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 36
Most-reported reactions
- Death — 12 reports (33.33%)
- Off Label Use — 4 reports (11.11%)
- Stomatitis — 4 reports (11.11%)
- Diarrhoea — 3 reports (8.33%)
- Therapy Interrupted — 3 reports (8.33%)
- Disease Progression — 2 reports (5.56%)
- Dyspnoea — 2 reports (5.56%)
- Gout — 2 reports (5.56%)
- Lip Swelling — 2 reports (5.56%)
- Product Dose Omission In Error — 2 reports (5.56%)
Other Oncology approved in United States
Frequently asked questions
Is Everolimus Tab. approved in United States?
Everolimus Tab. does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Everolimus Tab. in United States?
Chong Kun Dang Pharmaceutical is the originator. The local marketing authorisation holder may differ — check the official source linked above.